Corporate Profile for Alliance Pharmaceutical Corp., dated April 24, 1998.--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services. -0-
Published Date: April 24, 1998
Company Name: Alliance Pharmaceutical Corp.
Address: 3040 Science Park Road
San Diego, CA 92121
Main Telephone
Number: 619/558-4300
Internet Home
Page Address
(URL): http://www.allp.com
Chief Executive
Officer: Duane J. Roth
Chief Financial
Officer: Theodore D. Roth
Investor Relations
Contact: Gwen Rosenberg
Business number: 619/558-4375
Public Relations
Contact: Gwen Rosenberg
Business number: 619/558-4375
Trading Symbol/
Exchange: ALLP/Nasdaq
Industry: Pharmaceutical
Market Makers: Smith Barney Inc.; Cowen & Co.; Mayer & Schweitzer
Inc.; Oppenheimer & Co. Inc.; Lehman Brothers Inc.;
Knight Securities L.P.; Merrill Lynch, Pierce,
Fenner; Everen Securities Inc.
Company description: Alliance Pharmaceutical Corp. is a research and development company focused on transforming innovative discoveries into novel drug products. Principal Products are: - Oxygent(tm) -- an intravascular intravascular /in·tra·vas·cu·lar/ (in?trah-vas´ku-lar) within a vessel. in·tra·vas·cu·lar adj. Within one or more blood vessels. oxygen carrier in clinical development as a temporary "blood substitute" to reduce the need for donor blood during surgery and other periods of hypoxia hypoxia Condition in which tissues are starved of oxygen. The extreme is anoxia (absence of oxygen). There are four types: hypoxemic, from low blood oxygen content (e.g., in altitude sickness); anemic, from low blood oxygen-carrying capacity (e.g. (oxygen deficit). Oxygent does not transmit infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. , is compatible with all blood types, and has a shelf-life of approximately two years. Oxygent is being co-developed with Johnson & Johnson. - LiquiVent(r) -- an oxygen-carrying "liquid ventilation" drug administered into the lungs to open up air sacs air sacs sacs that communicate with the respiratory, air-filled membranous system in birds and primates. avian air sacs there are eight air sacs in the chicken: an unpaired cervical, an unpaired clavicular, a pair of cranial and facilitate gas exchange. LiquiVent has the potential to treat acute lung injury and respiratory distress Respiratory distress A condition in which patients with lung disease are not able to get enough oxygen. Mentioned in: Lung Cancer, Non-Small Cell resulting from infections, inhalation of toxic substances, or other causes. LiquiVent is being developed for infants through adults under FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. "fast track" regulations. - Imagent(r) -- a diagnostic contrast agent for enhancement of ultrasound images to aid in the assessment of heart function and perfusion, as well as the detection of tumors and blood flow abnormalities. In initial clinical studies, Imagent enhanced ultrasound signals from perfused tissues and blood vessels Blood vessels Tubular channels for blood transport, of which there are three principal types: arteries, capillaries, and veins. Only the larger arteries and veins in the body bear distinct names. using gray- scale, color Doppler, and harmonic ultrasound imaging harmonic ultrasound imaging Imaging A method designed to improve ultrasonographic detection of contrast agents in blood-containing cavities and vascularized tissue. See Contrast echocardiography. Cf Sonicated albumin, Transient response imaging. techniques. Imagent is being co-developed with Schering AG, Berlin. CONTACT: Alliance Pharmaceutical Corp. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion